AVNS
HealthcareAvanos Medical, Inc. · Medical - Devices · $1B
What is Avanos Medical, Inc.?
Avanos Medical is a small-cap medical technology company focused on non-opioid pain management and chronic care solutions. Headquartered in Alpharetta, Georgia, it serves hospitals, healthcare facilities, and distributors across multiple global regions.
Avanos generates revenue by selling medical devices directly to hospitals and healthcare providers, as well as through wholesale distributors. Its two main portfolios cover chronic care — including digestive health and respiratory management — and non-opioid pain solutions ranging from surgical pain pumps to minimally invasive interventional therapies. The company operates across North America, Europe, Asia Pacific, and Latin America.
Avanos Medical was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
- Enteral and neonatal feeding solutions (Mic-Key, Corpak, NeoMed)
- Airway management devices (Ballard, Microcuff, Endoclear)
- Surgical pain pumps (On-Q, ambIT) and cold compression therapy (Game Ready)
- Minimally invasive interventional pain therapy (Coolief)
Is AVNS a Good Stock to Buy?
UQS Score rates AVNS as Below Average overall.
The most constructive aspects of Avanos's profile sit in its Risk and Valuation pillars, both rated Good — suggesting the stock does not carry excessive financial risk relative to peers and is not priced at a steep premium. These two pillars provide a degree of downside cushion for investors evaluating entry points.
The Quality and Moat pillars are both rated Weak, pointing to below-average business fundamentals and limited competitive differentiation — meaningful concerns for a medical device company operating in a competitive landscape.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does AVNS pay dividends?
No — Avanos Medical, Inc. does not currently pay a dividend.
Avanos Medical does not currently pay a dividend. As a small-cap medical technology company, Avanos appears to prioritize reinvesting available capital into its product portfolio and commercial operations rather than returning cash to shareholders through distributions. Income-focused investors should factor this into their assessment.
When does AVNS report earnings?
Avanos Medical reports earnings on a quarterly cadence, typical for US-listed equities.
The company's Growth pillar is rated Neutral, reflecting a trajectory that is neither notably accelerating nor declining relative to sector peers. Revenue trends across its pain management and chronic care segments have been mixed, consistent with the competitive pressures visible in its Moat and Quality pillar ratings.
For the most recent quarter's results and guidance, visit Avanos Medical's investor relations page directly.
AVNS Price History
-38.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Avanos Medical, Inc.?
Based on Avanos Medical, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
AVNS Long-term Outlook
Avanos's fundamental outlook is shaped by a Neutral Growth profile alongside Weak Quality and Moat ratings — a combination that suggests modest, uncertain expansion rather than a clear upward trajectory. The Good Risk rating does indicate the balance sheet is not a near-term concern. Execution on its non-opioid pain and chronic care portfolios will be key to improving the overall quality profile over time.
Growth drivers
- Expanding adoption of non-opioid pain management solutions as healthcare systems seek alternatives to opioids
- International market penetration across Asia Pacific and Latin America
- Portfolio breadth across both chronic care and acute pain segments
Key risks
- Weak competitive moat leaves Avanos exposed to better-resourced medical device rivals
- Below-average business quality metrics limit margin and cash flow resilience
- Valuation rated Good but not deeply discounted, leaving limited buffer if growth disappoints
AVNS vs Peers
Avanos competes in the broader medical device space alongside companies with varying specializations and scale.
CONMED focuses on surgical devices and equipment used across a wider range of procedural specialties, giving it broader hospital penetration than Avanos's more targeted pain and chronic care focus.
IRadimed specializes in MRI-compatible medical devices, occupying a narrow but highly differentiated niche that contrasts with Avanos's broader chronic care and pain management portfolio.
SS Innovations is focused on robotic surgical systems, representing a higher-technology segment of the medical device market compared to Avanos's device-driven pain and feeding solutions.
Frequently Asked Questions
What does Avanos Medical do?
Avanos Medical develops and sells medical devices across two main areas: chronic care (including enteral feeding tubes and airway management products) and non-opioid pain management (including surgical pain pumps and minimally invasive pain therapies). The company markets to hospitals, healthcare facilities, and distributors worldwide.
Does AVNS pay dividends?
No, Avanos Medical does not currently pay a dividend. The company appears to direct available capital toward its product portfolio and operations rather than shareholder distributions. Investors seeking regular income should note this absence when evaluating AVNS.
When does AVNS report earnings?
Avanos Medical reports on a quarterly cadence, consistent with standard US-listed company practice. For confirmed dates and the latest quarterly results, check the investor relations section of the Avanos Medical website directly.
Is AVNS a good stock to buy?
UQS Score rates AVNS as Below Average overall. The Risk and Valuation pillars are rated Good, which provides some comfort, but the Weak Quality and Moat ratings highlight meaningful fundamental concerns. Investors should weigh these factors carefully and review the full pillar breakdown available to Pro members.
Is AVNS overvalued?
The UQS Valuation pillar for AVNS is rated Good, suggesting the stock is not trading at an elevated premium relative to its fundamentals. However, a reasonable valuation does not offset the Weak Quality and Moat ratings — value alone is rarely sufficient without underlying business strength.
How does AVNS compare to its competitors?
Avanos operates in a competitive medical device landscape alongside companies like CONMED, IRadimed, and SS Innovations. Each competitor occupies a different niche — from surgical equipment to robotic systems — while Avanos focuses specifically on pain management and chronic care. The full UQS comparison is available on each competitor's page.
What is AVNS's market cap bracket?
Avanos Medical is classified as a small-cap company. This places it in a segment of the market that can offer growth potential but typically carries higher volatility and less analyst coverage than large- or mega-cap peers in the healthcare sector.
Who founded Avanos Medical?
Avanos Medical was incorporated in 2014 as a spin-off from Kimberly-Clark, initially operating under the name Halyard Health before rebranding to Avanos Medical in June 2018. Founding leadership details are publicly available through the company's corporate history disclosures.
Is AVNS a long-term quality investment?
As a long-term quality indicator, the UQS Score rates AVNS as Below Average, driven by Weak Quality and Moat pillars. While the Good Risk rating suggests financial stability, sustained long-term quality typically requires stronger competitive positioning and business fundamentals than Avanos currently demonstrates.
What is the main competitive advantage of Avanos Medical?
Avanos's portfolio spans established brand names in enteral feeding and airway management alongside a growing non-opioid pain focus — a strategically relevant area as healthcare systems reduce opioid reliance. However, the UQS Moat pillar is rated Weak, indicating this advantage has not yet translated into durable competitive differentiation.
Unlock Full AVNS Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar scores for AVNS
- ✓Access detailed financial metrics behind the Quality and Moat ratings
- ✓Compare AVNS side-by-side with CNMD, IRMD, and other peers
- ✓Track changes to AVNS's pillar profile as new data is released
- ✓Screen for small-cap healthcare stocks with stronger quality profiles
Pro Analysis
AVNS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 39.0 | 15.1 | 19.0 | 41.8 | 77.5 | 69.8 | +0.1 |
| May 11, 2026 | 38.9 | 15.1 | 19.0 | 41.8 | 77.5 | 69.5 | +2.8 |
| May 10, 2026 | 36.1 | 1.6 | 19.0 | 41.8 | 77.5 | 72.9 | -2.8 |
| May 8, 2026 | 38.9 | 15.1 | 19.0 | 41.8 | 77.5 | 69.5 | -1.2 |
| May 3, 2026 | 40.1 | 21.5 | 19.0 | 41.8 | 74.4 | 69.8 | 0.0 |
| Apr 28, 2026 | 40.1 | 21.6 | 19.0 | 41.8 | 74.4 | 69.8 | 0.0 |
| Apr 23, 2026 | 40.1 | 21.5 | 19.0 | 41.8 | 74.4 | 69.8 | 0.0 |
| Apr 19, 2026 | 40.1 | 21.6 | 19.0 | 41.8 | 74.4 | 69.8 | -3.2 |
| Apr 15, 2026 | 43.3 | 21.6 | 19.0 | 41.8 | 74.4 | 90.7 | -1.3 |
| Apr 14, 2026 | 44.6 | 27.0 | 19.0 | 41.8 | 74.4 | 90.7 | -0.2 |
AVNS — Pillar Breakdown
Quality
— 15.1/100 (25%)Avanos Medical, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 41.8/100 (20%)Avanos Medical, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 77.5/100 (15%)Avanos Medical, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 69.8/100 (15%)Avanos Medical, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 19/100 (25%)Avanos Medical, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for AVNS.
Score Composition
Financial Data
More Stock Analysis
How is the AVNS UQS Score Calculated?
The UQS (Unified Quality Score) for Avanos Medical, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Avanos Medical, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Avanos Medical, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.